Production (Stage)
Aspire Biopharma Holdings, Inc.
ASBP
$0.225
$0.0010.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.16M | 524.20K | 235.60K | 86.40K | 220.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.43M | 640.50K | 242.60K | 96.90K | 231.00K |
| Operating Income | -1.43M | -640.50K | -242.60K | -96.90K | -231.00K |
| Income Before Tax | -15.94M | -738.50K | -242.60K | -96.90K | -231.00K |
| Income Tax Expenses | -- | 0.00 | 1.00K | -- | -- |
| Earnings from Continuing Operations | -15.94M | -738.50K | -243.60K | -96.90K | -231.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.94M | -738.50K | -243.60K | -96.90K | -231.00K |
| EBIT | -1.43M | -640.50K | -242.60K | -96.90K | -231.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.42 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.03 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.42 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.03 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 37.89M | 440.00M | 443.32M | 443.32M | 27.60M |
| Average Diluted Shares Outstanding | 37.89M | 440.00M | 443.32M | 443.32M | 27.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |